That is why blockade therapies targeting the PD-1/PD-L1 pathway with anti-PD-1 or anti-PD-L1 antibodies aim to suppress cancer cell survival and promote T effector cell generation, contributing to enhanced antitumor T cell responses and tumor regression. Here, PDCD1 is linked to cancer.